ValuEngine upgraded shares of Neurotrope (NASDAQ:NTRP) from a hold rating to a buy rating in a report published on Tuesday morning.
Other equities research analysts have also issued research reports about the company. Maxim Group began coverage on Neurotrope in a research report on Wednesday, May 16th. They issued a buy rating and a $16.00 price target on the stock. Zacks Investment Research downgraded Neurotrope from a hold rating to a sell rating in a research note on Friday, May 11th. Finally, Roth Capital began coverage on Neurotrope in a research note on Thursday, March 8th. They issued a buy rating and a $15.00 price objective on the stock.
Neurotrope opened at $9.59 on Tuesday, according to Marketbeat. Neurotrope has a 12 month low of $3.40 and a 12 month high of $9.94.
Neurotrope Company Profile
Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease (AD). Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.